M. Cid

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
Maria Cid, M C Cid, M. Cid, Maria‐cinta Cid, Mariac Cid, María C. Cid, M Cid, M. C. Cid, Maria-cinta Cid, María C Cid, Maria Cinta Cid, Maria C Cid, Maria C. Cid
Publication record
275 papers · 25,642 citations · H-index 70

PAPERS

EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice: 2023 update
2023244 citationsauthor #12
Safety of SARS-CoV-2 Vaccines in Patients with Autoimmune Diseases
20231 citationsauthor #9
Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis
2023201 citationsauthor #7
Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica
202377 citationsauthor #10
Human monocyte-derived suppressive cells (HuMoSC) for cell therapy in giant cell arteritis
20236 citationsauthor #17
Unmet needs and evidence gaps in hypereosinophilic syndrome and eosinophilic granulomatosis with polyangiitis.
202333 citationsauthor #3
Identification of new risk loci shared across systemic vasculitides points towards potential target genes for drug repurposing
202316 citationsauthor #17
Spanish cohort of VEXAS syndrome: clinical manifestations, outcome of treatments and novel evidences about UBA1 mosaicism
202358 citationsauthor #30
EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update
2023512 citationsauthor #6
Management of nonviral mixed cryoglobulinemia vasculitis refractory to rituximab: Data from a European collaborative study and review of the literature.
202217 citationsauthor #12
Predictors of hypogammaglobulinemia in ANCA-associated vasculitis after a rituximab-based induction: a multicentre study.
202224 citationsauthor #17
Blocking GM-CSF receptor α with mavrilimumab reduces infiltrating cells, pro-inflammatory markers and neoangiogenesis in ex vivo cultured arteries from patients with giant cell arteritis
202246 citationsauthor #13
Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial
202297 citationsauthor #1
The Sound of Interconnectivity; The European Vasculitis Society 2022 Report
20225 citationsauthor #6
Factors related to glucocorticoid-induced osteoporosis and fragility fractures in young subjects
20220 citationsauthor #7
Susac Syndrome: Description of a Single-Centre Case Series
20225 citationsauthor #5
Methylome and transcriptome profiling of giant cell arteritis monocytes reveals novel pathways involved in disease pathogenesis and molecular response to glucocorticoids
202235 citationsauthor #10
MO241: Nets and Terminal Complement Pathway as Potential Biomarkers for Complement Overactivation Assessment in Anca-Associated Vasculitis
20220 citationsauthor #5
The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma
202150 citationsauthor #16
An 80-year-old man with headache, orbital pain and elevated ESR: challenges in the diagnosis of a patient with suspected giant cell arteritis.
20211 citationsauthor #4
Large-vessel vasculitis
2021161 citationsauthor #4
Improvement of Treg immune response after treatment with tocilizumab in giant cell arteritis
202125 citationsauthor #27
The COVID-19 pandemic and ANCA-associated vasculitis – reports from the EUVAS meeting and EUVAS education forum
202142 citationsauthor #10
Prevalence of cardiovascular risk factors, the use of statins and of aspirin in Takayasu Arteritis
202111 citationsauthor #7
Response to mepolizumab according to disease manifestations in patients with eosinophilic granulomatosis with polyangiitis.
202124 citationsauthor #7
Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial.
202186 citationsauthor #6
Identification of a shared genetic risk locus for Kawasaki disease and IgA vasculitis by a cross-phenotype meta-analysis.
202110 citationsauthor #14
New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension
202115 citationsauthor #7
AB0475 CLINICAL RELEVANCE OF CLINICOPATHOLOGICAL PHENOTYPE AND ANTIBODY SPECIFICITY IN ANCA-ASSOCIATED VASCULITIS
20200 citationsauthor #6
THU0305 PREVALENCE AND CLINICAL OUTCOME OF INTERSTITIAL LUNG DISEASE IN ANCA ASSOCIATED VASCULITIS
20200 citationsauthor #9
FRI0010 GM-CSFR PATHWAY IS IMPLICATED IN PATHOGENIC INFLAMMATORY MECHANISMS IN GIANT CELL ARTERITIS
20206 citationsauthor #1
BSR guideline on diagnosis and treatment of giant cell arteritis
20201 citationsauthor #15
British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary.
202084 citationsauthor #15
PI3Kδ inhibition reshapes follicular lymphoma-immune microenvironment cross talk and unleashes the activity of venetoclax.
202028 citationsauthor #14
SAT0275 MAINTAINED BENEFIT IN HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB PLUS PREDNISONE TAPERING: RESULTS FROM THE OPEN-LABEL, LONG-TERM EXTENSION OF A PHASE 3 RANDOMIZED CONTROLLED TRIAL
20201 citationsauthor #7
British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis.
2020176 citationsauthor #15
Treatment of giant-cell arteritis: from broad spectrum immunosuppressive agents to targeted therapies.
202011 citationsauthor #1
PP2A Limits Endothelial Cell Apoptosis During Vascular Remodeling: A Complementary Approach To Kill Pathological Vessels?
20201 citationsauthor #8
Vertebral fracture risk in glucocorticoid-induced osteoporosis: the role of hypogonadism and corticosteroid boluses
202013 citationsauthor #9
Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes.
202032 citationsauthor #51
A multidisciplinary registry of patients with autoimmune and immune-mediated diseases with symptomatic COVID-19 from a single center
202024 citationsauthor #21
B55α/PP2A Limits Endothelial Cell Apoptosis During Vascular Remodeling
202025 citationsauthor #7
FRI0466 RISK FACTORS ASSOCIATED WITH THE DEVELOPMENT OF FRACTURES IN GLUCOCORTICOID TREATED PATIENTS. THE ROLE OF HYPOGONADISM
20190 citationsauthor #7
336. A PHASE 2, RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO TEST THE EFFICACY AND SAFETY OF MAVRILIMUMAB IN GIANT CELL ARTERITIS: STUDY DESIGN AND METHODOLOGY
20190 citationsauthor #3
THU0286 MANAGEMENT OF TAKAYASU ARTERITIS: A SYSTEMATIC LITERATURE REVIEW INFORMING THE 2018 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF LARGE VESSEL VASCULITIS
20192 citationsauthor #5
300. RENAL BALLOON ANGIOPLASTY IN TAKAYASU ARTERITIS (TA)
20190 citationsauthor #5
DECIPHERING THE CONTRIBUTION OF MACROPHAGES TO FOLLICULAR LYMPHOMA PATHOGENESIS: NEW INSIGHTS INTO THERAPY
20192 citationsauthor #14
Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis
201967 citationsauthor #5
185. GENETIC EVIDENCE OF EOSINOPHIL NUMBER UNDERPINNING PR3-AAV AND PLAUSIBLE HOST GENETIC PREDISPOSITION TO MICROBIAL DRIVERS OF DISEASE
20190 citationsauthor #8
Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial
2019195 citationsauthor #7
Trabecular bone score improves fracture risk assessment in glucocorticoid-induced osteoporosis.
201963 citationsauthor #6
HIV-associated vasculitis. Part II: histologic and angiographic diagnostic reconfirmation after an uncontrolled HIV infection and fatal outcome.
20192 citationsauthor #8
Long-Term Outcome of Tocilizumab for Patients with Giant Cell Arteritis: Results from Part 2 of a Randomized Controlled Phase 3 Trial
20199 citationsauthor #7
272 Acute phase reactant levels and prednisone doses at disease flare in patients with giant cell arteritis: prospective data from the GiACTA trial
20192 citationsauthor #8
Usefulness of imaging techniques in the management of giant cell arteritis
20190 citationsauthor #3
Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis.
2019108 citationsauthor #7
Maintained Benefit in Health-Related Quality of Life of Patients with Giant Cell Arteritis Treated with Tocilizumab Plus Prednisone Tapering : Results from the Open-Label, Long-Term Extension of a Phase 3 Randomized Controlled Trial
20190 citationsauthor #7
Glucocorticoid Dosages and Acute‐Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab
201998 citationsauthor #8
OP0140 LONG-TERM OUTCOME OF TOCILIZUMAB FOR PATIENTS WITH GIANT CELL ARTERITIS: RESULTS FROM PART 2 OF THE GIACTA TRIAL
201920 citationsauthor #7
O26 Effects of baseline prednisone dose on remission and disease flare in patients with giant cell arteritis treated with tocilizumab in the GiACTA trial
20190 citationsauthor #8
FRI0487 UTILITY OF TRABECULAR BONE SCORE(TBS) FOR FRACTURE RISK ASSESSMENT IN GLUCOCORTICOID-INDUCED OSTEOPOROSIS
20192 citationsauthor #7
A very late presentation of polymyalgia rheumatica in a patient with giant cell arteritis: recurrence or casual association?
20190 citationsauthor #4
SP0073 DIAGNOSIS OF GASTROINTESTINAL VASCULITIS
20190 citationsauthor #1
2018 Update of the EULAR recommendations for the management of large vessel vasculitis
2019852 citationsauthor #8
Time to Flare in Patients with New-Onset versus Relapsing Giant Cell Arteritis Treated with Tocilizumab or Placebo Plus Prednisone Tapering : 3-Year Results from a Randomized Controlled Phase 3 Trial
20193 citationsauthor #7
Management of Takayasu arteritis: a systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis
201963 citationsauthor #5
FRI0286 CUTANEOUS POLYARTERITIS NODOSA: A SUBSET OF SYSTEMIC PAN OR A DISEASE APART?
20191 citationsauthor #5
Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status
2019207 citationsauthor #9
FDG-PET/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: Joint procedural recommendation of the EANM, SNMMI, the PET Interest Group (PIG), and endorsed by the ASNC Writing group*:
20180 citationsauthor #12
Genetically distinct clinical subsets, and associations with asthma and eosinophil abundance, within Eosinophilic Granulomatosis with Polyangiitis
20189 citationsauthor #9
Cross-phenotype analysis of Immunochip data identifies KDM4C as a relevant locus for the development of systemic vasculitis
201828 citationsauthor #16
Expression and Function of IL12/23 Related Cytokine Subunits (p35, p40, and p19) in Giant-Cell Arteritis Lesions: Contribution of p40 to Th1- and Th17-Mediated Inflammatory Pathways
201845 citationsauthor #10
Treatment and outcomes in patients with IgG4-related disease using the IgG4 responder index.
201828 citationsauthor #11
351. EFFECTS OF BASELINE PREDNISONE DOSE ON REMISSION AND DISEASE FLARE IN PATIENTS WITH GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB IN A PHASE 3 RANDOMIZED CONTROLLED TRIAL
20180 citationsauthor #8
2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritis
201844 citationsauthor #4
FDG-PET/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC
2018404 citationsauthor #14
A TNFSF13B functional variant is not involved in systemic sclerosis and giant cell arteritis susceptibility
20184 citationsauthor #22
Pathogenesis of giant-cell arteritis: how targeted therapies are influencing our understanding of the mechanisms involved
201839 citationsauthor #2
Corrigendum: Analysis of the common genetic component of large-vessel vasculitides through a meta-Immunochip strategy
20175 citationsauthor #5
Occlusive vasculopathy in human immunodeficiency virus (HIV)-associated vasculitis: unusual clinical and imaging course.
20171 citationsauthor #7
Newly diagnosed vs. relapsing giant cell arteritis: Baseline data from the GiACTA trial.
201763 citationsauthor #7
Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts
201724 citationsauthor #4
Efficacy and safety of tocilizumab in patient subgroups with new-onset and relapsing giant cell arteritis from a randomized, double-blind, placebo-controlled, phase 3 trial
20171 citationsauthor #8
Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis
2017746 citationsauthor #10
Association of a TNFSF13B (BAFF) regulatory region single nucleotide polymorphism with response to rituximab in antineutrophil cytoplasmic antibody-associated vasculitis.
201730 citationsauthor #18
AB0575 Retrospective survey of concomitant autoimmune diseases and autoantibodies in a cohort of patients with anca-associated vasculitis (AAV)
20170 citationsauthor #7
8 Aortitis and Aortic Aneurysm in Systemic Vasculitis
20170 citationsauthor #6
Trial of Tocilizumab in Giant‐Cell Arteritis
20171,074 citationsauthor #8
Analysis of the common genetic component of large-vessel vasculitides through a meta-Immunochip strategy
201767 citationsauthor #5
Biological treatments in giant cell arteritis & Takayasu arteritis.
201739 citationsauthor #10
A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis.
201784 citationsauthor #132
Characterization of isolated retinal vasculitis. Analysis of a cohort from a single center and literature review.
201725 citationsauthor #8
A Genome-Wide Association Study Identifies Plasminogen and P4HA2 as Novel Susceptibility Genes for Giant Cell Arteritis
20170 citationsauthor #6
SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma.
201796 citationsauthor #8
MEPOLIZUMAB FOR THE TREATMENT OF PATIENTS WITH EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS: A PHASE III RANDOMISED, PLACEBO-CONTROLLED TRIAL
20171 citationsauthor #10
Serum osteopontin: a biomarker of disease activity and predictor of relapsing course in patients with giant cell arteritis. Potential clinical usefulness in tocilizumab-treated patients
201746 citationsauthor #15
Recent advances in our understanding of giant cell arteritis pathogenesis.
2017198 citationsauthor #6
Virologic, Clinical, and Immune Response Outcomes of Patients With Hepatitis C Virus–Associated Cryoglobulinemia Treated With Direct‐Acting Antivirals
2017134 citationsauthor #5
Endothelin-1 promotes vascular smooth muscle cell migration across the artery wall: a mechanism contributing to vascular remodelling and intimal hyperplasia in giant-cell arteritis
201783 citationsauthor #12
The European Vasculitis Society 2016 Meeting Report
201723 citationsauthor #4

TIMELINE

1984 0 citations

1985 6 citations

1986 60 citations

1987 138 citations

1988 92 citations

1989 126 citations

1990 30 citations

1991 17 citations

1992 183 citations

1993 0 citations

1994 64 citations

1995 94 citations

1996 171 citations

1997 9 citations

1998 13 citations

1999 261 citations

2000 5 citations

2001 25 citations

2002 1,011 citations

2003 546 citations

2004 582 citations

2005 78 citations

2006 32 citations

2007 1,192 citations

2008 1,848 citations

2009 256 citations

2010 320 citations

2011 189 citations

2012 2,234 citations

2013 5,755 citations

2014 744 citations

2015 1,060 citations

2016 1,292 citations

2017 2,740 citations

2018 601 citations

2019 1,696 citations

2020 402 citations

2021 425 citations

2022 229 citations

2023 1,148 citations

M. Cid

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT